Related Experiment Video
Updated: Jan 20, 2026
In Vivo Imaging of Cerebral Vessels and Amyloid Plaques in an Alzheimer’s Disease Mouse Model
Published on: June 17, 2025
Cerebrovascular disease: Neuroimaging of cerebral small vessel disease
C Elizabeth Shaaban1, Dana R Jorgensen2, Peter J Gianaros3
1Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States; Center for the Neural Basis of Cognition, University of Pittsburgh, Pittsburgh, PA, United States.
Abstract:
The cerebral microvasculature is exceptionally vulnerable to changes due to aging. Both the radiological and clinical manifestations of cerebral small vessel disease (cSVD) in older age are highly heterogeneous, ranging from no symptomatology to devastating neurocognitive complications, including stroke, dementia, and depression. To date, the exact pathogenesis of cSVD is unknown; neither prevention nor treatments are currently available for this potentially very disabling condition. This chapter reviews recent advances in neuroimaging methodologies that have improved our understanding of the appearance of cSVD and the underlying mechanisms. We will discuss new venues for future research focusing on: (a) methodologies to measure early stages of cSVD, examining damage primarily in small vessels and secondarily in parenchyma; and (b) lifespan study designs to capture the onset and evolution of cSVD over time, as well as the temporality of exposure to risk factors.
Related Concept Videos
In Vivo Imaging of Cerebral Vessels and Amyloid Plaques in an Alzheimer’s Disease Mouse Model
14:27Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
13:16Intravascular Perfusion of Carbon Black Ink Allows Reliable Visualization of Cerebral Vessels
04:29A Visual Approach for Inducing Dolichoectasia in Mice to Model Large Vessel-Mediated Cerebrovascular Dysfunction
07:30Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
06:19Reconstruction of the Blood-Brain Barrier In Vitro to Model and Therapeutically Target Neurological Disease

